Hello,

For the sites that have an active residency program and residents. Can you please tell me if you mandate ACLS/BLS/PALS to your preceptors?

Thank you,

We have had some great catches where low dose anti-biotics are ordered for pediatric patients (i.e. 150 mg vs. 150 mg/kg). What Epic solutions have you utilized to monitor this? Hesitant to turn on all low dose warnings across the system due to the potential for alert fatigue.

If you have a tech-check-tech program, What quality metrics are you tracking?

Hi,
Would love to hear if anyone has a requirement for a naloxone PRN order for specific patient populations or when specific medications are ordered. For example, when insulin is ordered we have a few hypoglycemia orders that must be added to the patient's MAR as PRN. So the question arose, should we do this with opioids & naloxone.

Thank you!

Hi
We are in desperate need of a comprehensive insulin policy. Does anyone have a general insulin policy they'd be willing to share? I would love to see what others have so we can get a jumping off point.

Thanks

Lindsey Eick, PharmD, BCPS
Medication Safety Supervisor
OHSU

For chemotherapy agents that vaporize (e.g., Carmustine, Cyclophosphamide, Doxorubicin, Fluorouracil), has anyone completed a hazard/risk assessment of exposure once they have been further diluted for administration? Specifically, do you handle a spill of a diluted preparation the same as you would (e.g, require PAPR), if undiluted liquid was spilled?

Kind regards,
Ronda Whipple PharmD

For those interested in joining today's MSOS Briefing webinar, here is the registration link to sign up: https://ecri.zoom.us/webinar/register/WN_uQOO_Hg9Q4y8y9h6R_h-PA

Topics:
The Fellowship of the Pumps: Pump Integration System-Wide
Supporting Safety During Code Response: The PALS Copilot app
ISMP Update

Hope to see you there!

Does anyone have a policy or order set you could share for management of patients undergoing thrombolysis?

Thanks,
Stacie Ethington MSN, RN
Nebraska Medicine

One of my facilities frequently administers methocarbamol slow IV. Recently, they acquired the generic product from Somerset Therapeutics and have had a few instances of phlebitis, even when diluted and given very slowly. I'm reaching out to see if this is an isolated issue or if other facilities administering slow IV push have noted an uptick in phlebitis. Of note, they have not had this issue in the past with the brand name product.

We’re exploring opportunities to expand our medication safety team and would appreciate insights from other organizations.

For those of you with multiple team members working under the umbrella of medication safety:

-What titles do you use for those roles?

-Do you have more than one Medication Safety Officer?

-Are your team members titled as Medication Safety Pharmacists, Nurses, Coordinators, or something else?

Any details on structure or role differentiation would be incredibly helpful. Thanks in advance for your input!